Abstract
637P A phase II study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and Hepatic Artery Infusion Chemotherapy (HAIC) for advanced Colorectal Cancer Liver Metastases (CRLM)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have